Antimicrobial treatment for intra-abdominal infections (Q37000729)

17 August 2017

1 reference

title

Antimicrobial treatment for intra-abdominal infections (English)

1 reference

17 August 2017

John E Mazuski

1

1 reference

17 August 2017

language of work or name

English

0 references

publication date

1 December 2007

1 reference

Expert Opinion on Pharmacotherapy

17 August 2017

published in

1 reference

17 August 2017

volume

8

1 reference

17 August 2017

issue

17

1 reference

17 August 2017

page(s)

2933-2945

1 reference

The continuing challenge of intra-abdominal infection

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2933

Intra-abdominal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2933

Critical issues in the clinical management of complicated intra-abdominal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2933

Intensive care unit management of intra-abdominal infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2933

Empiric treatment of nosocomial intra-abdominal infections: a focus on the carbapenems

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2933

The microbiology of postoperative peritonitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2933

The international sepsis forum consensus conference on definitions of infection in the intensive care unit

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2933

Microbiology of polymicrobial abscesses and implications for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2933

In vitro susceptibilities of aerobic and facultative gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: the 2002 Study for Monitoring Antimicrobial Resistance Trends (SMART).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2933

Surgical Infections withEnterococcus: Outcome in Patients Treated with Ertapenem versus Piperacillin-Tazobactam

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2933

Postoperative enterococcal infection after treatment of complicated intra-abdominal sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2933

Antimicrobial susceptibility among pathogens collected from hospitalized patients in the United States and in vitro activity of tigecycline, a new glycylcycline antimicrobial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2933

Vancomycin-resistant enterococci: a road map on how to prevent the emergence and transmission of antimicrobial resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2933

Intra-abdominal anaerobic infections: bacteriology and therapeutic potential of newer antimicrobial carbapenem, fluoroquinolone, and desfluoroquinolone therapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2933

Multicenter survey of the changing in vitro antimicrobial susceptibilities of clinical isolates of Bacteroides fragilis group, Prevotella, Fusobacterium, Porphyromonas, and Peptostreptococcus species

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2933

Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2933

Results from the ARTEMIS DISK Global Antifungal Surveillance Study: a 6.5-year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk diffusion testing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2933

The Surgical Infection Society guidelines on antimicrobial therapy for intra-abdominal infections: an executive summary

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2933

Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2933

The Surgical Infection Society guidelines on antimicrobial therapy for intra-abdominal infections: evidence for the recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2933

Aminoglycosides for intra-abdominal infection: equal to the challenge?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2933

In vitro activity of moxifloxacin against 923 anaerobes isolated from human intra-abdominal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2933

The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2933

Monotherapy with a broad-spectrum beta-lactam is as effective as its combination with an aminoglycoside in treatment of severe generalized peritonitis: a multicenter randomized controlled trial. The Severe Generalized Peritonitis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2933

Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2933

Are there patients with peritonitis who require empiric therapy for enterococcus?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2933

Approaches to vancomycin-resistant enterococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2933

Antimicrobial agents for treatment of serious infections caused by resistant Staphylococcus aureus and enterococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2933

Fungal infection but not type of bacterial infection is associated with a high mortality in primary and secondary infected pancreatic necrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2933

Antibiotic resistance in postoperative infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2933

A consensus statement on empiric therapy for suspected gram-positive infections in surgical patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2933

In vitro activity of quinupristin/dalfopristin, linezolid, telithromycin and comparator antimicrobial agents against 13 species of coagulase-negative staphylococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2933

The in vitro activity of daptomycin against 514 Gram-positive aerobic clinical isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2933

Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2933

Candida infections in the intensive care unit: epidemiology, risk factors and therapeutic strategies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2933

New agents for the treatment of fungal infections: clinical efficacy and gaps in coverage

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2933

The changing epidemiology of invasive fungal infections: new threats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2933

Antimicrobial therapy for patients with severe sepsis and septic shock: an evidence-based review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2933

In vitro activity of voriconazole and other antifungal agents against clinical isolates of Candida glabrata and Candida krusei

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2933

Caspofungin activity against clinical isolates of fluconazole-resistant Candida

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2933

Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2933

Clinical significance of Candida isolated from peritoneum in surgical patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2933

Preventing Antimicrobial-Resistant Bacterial Infections in Surgical Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2933

Infective complications according to duration of antibiotic treatment in acute abdomen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2933

Minimal antibiotic therapy after emergency abdominal surgery: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2933

Implications of leukocytosis and fever at conclusion of antibiotic therapy for intra-abdominal sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2933

Predictors of recurrence of fulminant bacterial peritonitis after discontinuation of antibiotics in open management of the abdomen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.17.2933

10.1517/14656566.8.17.2933

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference